TAK-385 enters into phase 2 clinical trials in Japan
29 August 2011 | By Takeda Pharmaceutical Company Limited
TAK-385 used for the treatment of endometriosis and uterine fibroids...
List view / Grid view
News
Pradaxa® (dabigatran etexilate, 150mg bid) shows significant reduction in the risk of stroke
New data from two RE-LY® trial subgroup analyses show that dabigatran etexilate 150mg bid consistently reduces the risk of stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet [1] or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil. [2] The relative benefits…
ELIQUIS® (apixaban) superior to Warfarin for the reduction of stroke or systemic embolism
28 August 2011 | By Bristol-Myers Squibb Company, Pfizer
Significantly less major bleeding in patients with Atrial Fibrillation in Phase 3 ARISTOTLE trial...
Abbott receives FDA approval for ALK gene test
26 August 2011 | By Abbott
Represents significant advance in personalised medicine for patients with non-small-cell lung cancer...
Novo Nordisk to build new corporate centre
25 August 2011 | By Novo Nordisk
Novo Nordisk is investing around 1 billion Danish kroner (134 million euros) in two new office buildings with surrounding green space in Bagsværd, Denmark...
Linagliptin receives approval in Europe for treatment of type 2 diabetes
25 August 2011 | By Eli Lilly and Company, Boehringer Ingelheim
Linagliptin is the only DPP-4 inhibitor to be approved at one dosage strength for adults with type 2 diabetes in Europe, without any need for dose adjustments...
Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe
25 August 2011 | By Boehringer Ingelheim
Marketing Authorisation from the European Commission for Trajenta® (linagliptin)...
ERT appoints Linda Deal Head of Health Outcomes Research
24 August 2011 | By The Scott Partnership
ERT, announced the appointment of Linda Deal to lead ERT's Health Outcomes Research initiatives...
Bristol-Myers Squibb and Pfizer announce data presentations
23 August 2011 | By Pfizer
New data presentations from largest Phase 3 Clinical Trial Program for Stroke Prevention in Atrial Fibrillation...
Amgen announces PDUFA date for XGEVA® supplemental Biologics License Application
22 August 2011 | By Amgen
The FDA will target a PDUFA action date of April 26, 2012 for the sBLA...
FDA Clears Abbott’s Genetic FISH Panel for Leukemia Patient Prognosis
22 August 2011 | By
Abbott has received 510k clearance from the FDA...
GSK takes minority stake in new spin out Autifony Therapeutics
22 August 2011 | By GlaxoSmithKline
GSK will receive a 25.4% minority equity stake, representing a £1,250,000 investment, in Autifony Therapeutics Limited...
Wyatt Technology’s FFF-MALS provides efficient Liposome Characterization
19 August 2011 | By The Scott Partnership
FFF technology combined with MALS & QELS enables rapid measurements of particle size, size distribution, particle count, & structure...
EMA accepts marketing authorization application for Ridaforolimus, investigational mTOR inhibitor
18 August 2011 | By
Merck to pay ARIAD $25 million milestone payment for acceptance of filing...
Pfizer announces EMA acceptance of regulatory submissions for two investigational cancer therapies
17 August 2011 | By Pfizer
EMA accepted Pfizer’s regulatory submissions for review of two investigational compounds...
